Page 84 - AN-3-3

Advanced Neurology mTOR inhibition in epilepsy

doi: 10.4103/ijn.IJN_304_16 Efficacy of Afinitor (Everolimus) in Patients with Refractory
Seizures Who Have Focal Cortical Dysplasia Type II (FCD
77. Davies M, Saxena A, Kingswood JC. Management of
everolimus-associated adverse events in patients with II); 2021. Available from: https://clinicaltrials.gov/study/
tuberous sclerosis complex: A practical guide. Orphanet J NCT03198949 [Last accessed on 2024 May 30].
Rare Dis. 2017;12(1):35. 88. Myers KA, Scheffer IE. DEPDC5 as a potential
therapeutic target for epilepsy. Expert Opin Ther Targets.
doi: 10.1186/s13023-017-0581-9
2017;21(6):591-600.
78. Küper MA, Schölzl N, Traub F, et al. Everolimus interferes
with the inflammatory phase of healing in experimental doi: 10.1080/14728222.2017.1316715
colonic anastomoses. J Surg Res. 2011;167(1):158-165. 89. Kearney H, Doyle M, Moloney P. Everolimus as a Precision
Medicine for Epilepsy Due to Pathogenic Variants in DEPDC5.
doi: 10.1016/j.jss.2009.07.013
American Epilepsy Society; 2020. Available from: https://
79. Curatolo P, Bjørnvold M, Dill PE, et al. The role of mTOR aesnet.org/abstractslisting/everolimus-as-a-precision-
inhibitors in the treatment of patients with tuberous medicine-for-epilepsy-due-to-pathogenic-variants-in-
sclerosis complex: Evidence-based and expert opinions. depdc5 [Last accessed on 2024 Apr 29].
Drugs. 2016;76(5):551-565.
90. Moloney PB, Kearney H, Benson KA, et al. Everolimus
doi: 10.1007/s40265-016-0552-9 precision therapy for the GATOR1-related epilepsies: A case
series. Eur J Neurol. 2023;30(10):3341-3346.
80. Parker WE, Orlova KA, Parker WH, et al. Rapamycin
prevents seizures after depletion of STRADA in a doi: 10.1111/ene.15975
rare neurodevelopmental disorder. Sci Transl Med. 91. Sánchez-Espino LF, Ivars M, Antoñanzas J, Baselga E. Sturge-
2013;5(182):182ra53.
Weber syndrome: A review of pathophysiology, genetics,
doi: 10.1126/scitranslmed.3005271 clinical features, and current management approach. Appl
Clin Genet. 2023;16:63-81.
81. Xu Q, Uliel-Sibony S, Dunham C, et al. mTOR inhibitors
as a new therapeutic strategy in treatment resistant epilepsy doi: 10.2147/TACG.S363685
in hemimegalencephaly: A case report. J Child Neurol. 92. Triana Junco PE, Sánchez-Carpintero I, López-Gutiérrez JC.
2019;34(3):132-138.
Preventive treatment with oral sirolimus and aspirin in
doi: 10.1177/0883073818813238 a newborn with severe Sturge-Weber syndrome. Pediatr
Dermatol. 2019;36(4):524-527.
82. Hadouiri N, Darmency V, Guibaud L, et al. Compassionate
use of everolimus for refractory epilepsy in a patient doi: 10.1111/pde.13841
with MTOR mosaic mutation. Eur J Med Genet. 93. Sun B, Han T, Wang Y, Gao Q, Cui J, Shen W. Sirolimus as a
2020;63(11):104036.
potential treatment for Sturge-weber syndrome. J Craniofac
doi: 10.1016/j.ejmg.2020.104036 Surg. 2021;32(1):257-260.
83. Leitner DF, Kanshin E, Askenazi M, et al. Pilot study doi: 10.1097/SCS.0000000000007034
evaluating everolimus molecular mechanisms in tuberous 94. Sebold AJ, Day AM, Ewen J, et al. Sirolimus treatment in
sclerosis complex and focal cortical dysplasia. PLoS One. Sturge-weber syndrome. Pediatr Neurol. 2021;115:29-40.
2022;17(5):e0268597.
doi: 10.1016/j.pediatrneurol.2020.10.013
doi: 10.1371/journal.pone.0268597
95. Kalafut KC, Mitchell SJ, MacArthur MR, Mitchell JR.
84. Shiraishi H, Teramoto T, Yokoshiki S, et al. Efficacy of Short-term ketogenic diet induces a molecular response
sirolimus for epileptic seizures in childhood associated with that is distinct from dietary protein restriction. Front Nutr.
focal cortical dysplasia type II. Brain Dev. 2023;45(6):343-347.
2022;9:839341.
doi: 10.1016/j.braindev.2023.02.005
doi: 10.3389/fnut.2022.839341
85. Kato M, Kada A, Shiraishi H, et al. Sirolimus for epileptic 96. Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR,
seizures associated with focal cortical dysplasia type II. Ann Freeman JM. Tuberous sclerosis complex and the ketogenic
Clin Transl Neurol. 2022;9(2):181-192.
diet. Epilepsia. 2005;46(10):1684-1686.
doi: 10.1002/acn3.51505
doi: 10.1111/j.1528-1167.2005.00266.x
86. Park J, Kim SH, Hahn J, et al. Population pharmacokinetics 97. Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical
of everolimus in patients with seizures associated with focal management of children receiving dietary therapies for
cortical dysplasia. Front Pharmacol. 2023;14:1197549.
epilepsy: Updated recommendations of the international
doi: 10.3389/fphar.2023.1197549 Ketogenic diet study group. Epilepsia Open. 2018;3(2):175-192.
87. Yonsei University. A Study Investigating the Anti-epileptic doi: 10.1002/epi4.12225

Volume 3 Issue 3 (2024) 20 doi: 10.36922/an.3568